Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women

Bone

Volumn 26, Issue 6, 2000, Pages 561-569

  Bjarnason, N H ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone markers; Bone mass; Bone turnover; Monitoring; Osteoporosis; Prevention

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; ESTRADIOL; GESTODENE; OSTEOCALCIN; PLACEBO;

ADULT; ARTICLE; BONE ATROPHY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MONITORING; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; DOUBLE-BLIND METHOD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 0034065195     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00272-6     Document Type: Article

References (29)

1. Bjarnason N.H., Bjarnason K., Haarbo J., Christiansen C. Tibolone Prevention of bone loss in late postmenopausal women . J Clin Endocrinol Metab. 81:1996;2419-2422.
2. Bjarnason N.H., Bjarnason K., Hassager C., Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone. 20:1997;151-155.
3. Bjarnason, N. H., Byrjalsen, I., Hassager, C., Haarbo, J., and Christiansen, C. Low dose estradiol in combination with gestodene is fully preventive in early postmenopausal women. Am J Obstet Gynecol. In press.
4. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immuno assay for a new markers of bone resorption (CrossLaps) Follow-up on hormone replacement therapy and osteoporosis risk assessment . J Clin Endocrinol Metab. 80:1995;864-868.
5. Chesnut C.H. III, Bell N.H., Clark G.S., Drinkwater B.L., English S.C., Johnson C.C. Jr, Notelovitz M., Rosen C., Cain D.F., Flessland K.A., Mallinak N.J. Hormone replacement therapy in postmenopausal women Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density . Am J Med. 102:1997;29-37.
6. Christiansen C., Christiansen M.S., Larsen N.-E., Transbøl I. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab. 55:1982;1124-1130.
7. Christiansen C., Christiansen M.S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1:(8218):1981;459-461.
8. Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 7:1-6; 1997.
9. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.-C., Shah A.S., Huster W.J., Draper M.W., Christiansen C. The effects of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
10. Garnero P., Darte C., Delmas P.D. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 24:1999;603-609.
11. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1994;1693-1700.
12. Genant H.K., Engelke K., Fuerst T., Gluer C.C., Grampp S., Harris S.T., Jergas M., Lang T., Lu Y., Majumdar S., Mathur A., Takada M. Noninvasive assessment of bone mineral and structure state of the art . J Bone Miner Res. 11:1996;707-730.
13. Greenspan S.L., Parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women A randomized clinical trial . J Bone Miner Res. 13:1998;1431-1438.
14. Herd R.J., Balena R., Blake G.M., Ryan P.J., Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy A 2-year, double-blind, placebo-controlled study . Am J Med. 103:1997;92-99.
15. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M., Yates A.J. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 338:1998;485-492.
16. Little R.R., England J.D., Wiedmeyer H.M., McKenzie E.M., Pettitt D.J., Knowler W.C., Goldstein D.E. Relationship of glycosylated hemoglobin to oral glucose tolerance. Implications for diabetes screening. Diabetes. 37:1988;60-64.
17. Mortensen L., Charles P., Bekker P.J., Digennaro J., Johnston C.C. Jr. Risedronate increases bone mass in an early postmenopausal population Two years of treatment plus one year of follow-up . J Clin Endocrinol Metab. 83:1998;396-402.
18. Peters A.L., Davidson M.B., Schriger D.L., Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus An analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels . JAMA. 276:1996;1246-1252.
19. Ravn P., Christensen J.O., Baumann M., Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment Prediction of bone mass changes during treatment . Bone. 22:1998;559-564.
20. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone. 24:1999;237-244.
21. Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study . Bone. 19:1996;527-533.
22. Ravn, P., Hosking, D., Thompson, D., Cizza, G., McClung, M., Yates, A. J., Bjarnason, N. H., and Christiansen, C., for the EPIC Study Group. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort (EPIC) study. J Clin Endocrinol Metab. In press.
23. Ravnikar, V. A. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventive health benefits? Womens Health Issues 2:75-80, discussion 80-82; 1992.
24. Riis B.J., Overgaard K., Christiansen C. Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteopor Int. 5:1995;276-280.
25. Rosen C.J., Chesnut C.H. III, Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 82:1997;1904-1910.
26. Rosen H.N., Moses A.C., Garber J., Ross D.S., Lee S.L., Greenspan S.L. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int. 63:1998;363-368.
27. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 44:1998;2281-2289.
28. Rosenquist C., Qvist P., Bjarnason N.H., Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 41:1995;1439-1445.
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.